ABVD Plus Rituximab ABVD Alone for Advanced Stage, High-risk Classical Hodgkin Lymphoma: a Randomized Phase 2 Study

Overview

Journal Haematologica

Specialty Hematology

Date 2018 Sep 8

PMID 30190343

Citations 9

Authors

Paolo Strati

Michelle A Fanale

Yasuhiro Oki

Francesco Turturro

Luis E Fayad

Nancy L Bartlett

Douglas E Gladstone

Yvette L Kasamon

Carol S Portlock

Wyndham H Wilson

Andre Goy

Anas Younes

Hun Ju Lee

Affiliations

Soon will be listed here.

Citing Articles

What We Know and Do Not Yet Know About the Canine Model of Lymphoma in Human Medicine-The Current State of Knowledge.

Bedkowska D, Al-Ameri S, Wieczorek A, Bubak J, Miszczak M Cancers (Basel). 2025; 17(4).

PMID: 40002191 PMC: 11853190. DOI: 10.3390/cancers17040596.

Successful Treatment of a Patient Presenting with Simultaneous Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma: A Case Report.

Lee J, Han M, Baek D Am J Case Rep. 2025; 26():e945435.

PMID: 39748486 PMC: 11706436. DOI: 10.12659/AJCR.945435.

Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances.

Munir F, Hardit V, Sheikh I, Alqahtani S, He J, Cuglievan B Int J Mol Sci. 2023; 24(12).

PMID: 37373245 PMC: 10298672. DOI: 10.3390/ijms241210095.

CD20 expression is closely associated with Epstein-Barr virus infection and an inferior survival in nodular sclerosis classical Hodgkin lymphoma.

Zhao X, Ma Y, Bian H, Liu Z Front Oncol. 2022; 12:993768.

PMID: 36147921 PMC: 9486205. DOI: 10.3389/fonc.2022.993768.

Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial.

Hochberg J, Basso J, Shi Q, Klejmont L, Flower A, Bortfeld K J Immunother Cancer. 2022; 10(5).

PMID: 35584865 PMC: 9119160. DOI: 10.1136/jitc-2021-004445.

References

Younes A, Carbone A . Clinicopathologic and molecular features of Hodgkin's lymphoma. Cancer Biol Ther. 2003; 2(5):500-7. DOI: 10.4161/cbt.2.5.510. View

Voog E, Morschhauser F, Solal-Celigny P . Neutropenia in patients treated with rituximab. N Engl J Med. 2003; 348(26):2691-4; discussion 2691-4. DOI: 10.1056/NEJM200306263482620. View

Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci A . Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol. 1998; 16(3):818-29. DOI: 10.1200/JCO.1998.16.3.818. View

Kasamon Y, Jacene H, Gocke C, Swinnen L, Gladstone D, Perkins B . Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012; 119(18):4129-32. PMC: 3359734. DOI: 10.1182/blood-2012-01-402792. View

Fanale M, Cheah C, Rich A, Medeiros L, Lai C, Oki Y . Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017; 130(4):472-477. PMC: 5578726. DOI: 10.1182/blood-2017-02-766121. View

Kim S, Fridlender Z, Dunn R, Kehry M, Kapoor V, Blouin A . B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J Immunother. 2008; 31(5):446-57. DOI: 10.1097/CJI.0b013e31816d1d6a. View

Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F . Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol. 2010; 152(5):551-60. DOI: 10.1111/j.1365-2141.2010.08485.x. View

Rehwald U, Schulz H, Reiser M, Sieber M, Staak J, Morschhauser F . Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 2003; 101(2):420-4. DOI: 10.1182/blood.V101.2.420. View

Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez M, Fiumara P . A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003; 98(2):310-4. DOI: 10.1002/cncr.11511. View

10.

Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R . Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin.... Lancet Oncol. 2017; 18(4):454-463. DOI: 10.1016/S1470-2045(17)30103-1. View

11.

Rassidakis G, Medeiros L, Viviani S, Bonfante V, Vassilakopoulos T, Mesina O . CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol. 2002; 20(5):1278-87. DOI: 10.1200/JCO.2002.20.5.1278. View

12.

Connors J, Radford J . Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2018; 378(16):1560-1561. DOI: 10.1056/NEJMc1802363. View

13.

Younes A, Oki Y, McLaughlin P, Copeland A, Goy A, Pro B . Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012; 119(18):4123-8. PMC: 3359733. DOI: 10.1182/blood-2012-01-405456. View